Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) - Research analysts at B. Riley issued their Q4 2024 earnings per share estimates for shares of Viking Therapeutics in a research report issued on Thursday, November 21st. B. Riley analyst M. Mamtani expects that the biotechnology company will earn ($0.24) per share for the quarter. B. Riley has a "Strong-Buy" rating on the stock. The consensus estimate for Viking Therapeutics' current full-year earnings is ($0.98) per share. B. Riley also issued estimates for Viking Therapeutics' Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.23) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($2.53) EPS and FY2028 earnings at ($1.83) EPS.
Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last posted its quarterly earnings results on Wednesday, October 23rd. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.02. During the same period in the prior year, the firm posted ($0.23) earnings per share.
Other equities analysts have also recently issued reports about the stock. William Blair reaffirmed an "outperform" rating on shares of Viking Therapeutics in a research note on Wednesday, November 20th. Oppenheimer reaffirmed an "outperform" rating and set a $138.00 price objective on shares of Viking Therapeutics in a research note on Wednesday, September 25th. HC Wainwright increased their target price on Viking Therapeutics from $90.00 to $102.00 and gave the company a "buy" rating in a research note on Monday, November 4th. StockNews.com upgraded Viking Therapeutics to a "sell" rating in a research report on Tuesday, October 15th. Finally, Morgan Stanley reiterated an "overweight" rating and issued a $105.00 price target on shares of Viking Therapeutics in a research report on Thursday, September 12th. One equities research analyst has rated the stock with a sell rating, ten have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $109.73.
Read Our Latest Stock Report on VKTX
Shares of NASDAQ VKTX opened at $52.59 on Monday. Viking Therapeutics has a 1 year low of $11.55 and a 1 year high of $99.41. The firm's 50-day moving average is $63.73 and its 200-day moving average is $60.25. The firm has a market capitalization of $5.86 billion, a PE ratio of -56.55 and a beta of 1.00.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Oak Ridge Investments LLC bought a new position in Viking Therapeutics in the third quarter valued at approximately $837,000. Oppenheimer & Co. Inc. boosted its holdings in shares of Viking Therapeutics by 43.5% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 102,324 shares of the biotechnology company's stock valued at $6,478,000 after buying an additional 31,011 shares during the last quarter. Nvwm LLC bought a new position in shares of Viking Therapeutics in the third quarter valued at $999,000. Chartwell Investment Partners LLC grew its stake in shares of Viking Therapeutics by 88.0% in the third quarter. Chartwell Investment Partners LLC now owns 36,666 shares of the biotechnology company's stock valued at $2,322,000 after buying an additional 17,159 shares in the last quarter. Finally, Aptus Capital Advisors LLC raised its position in Viking Therapeutics by 34.1% during the third quarter. Aptus Capital Advisors LLC now owns 38,143 shares of the biotechnology company's stock worth $2,415,000 after acquiring an additional 9,699 shares in the last quarter. Institutional investors and hedge funds own 76.03% of the company's stock.
In other news, CEO Brian Lian sold 216,130 shares of Viking Therapeutics stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $70.83, for a total value of $15,308,487.90. Following the sale, the chief executive officer now directly owns 2,304,927 shares in the company, valued at $163,257,979.41. This trade represents a 8.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lawson Macartney sold 2,000 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $68.67, for a total transaction of $137,340.00. Following the transaction, the director now owns 47,965 shares of the company's stock, valued at $3,293,756.55. The trade was a 4.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 371,117 shares of company stock worth $27,140,009 over the last three months. Corporate insiders own 4.70% of the company's stock.
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Viking Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.
While Viking Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.